left-caret

NEWS

Merck to Acquire Afferent Pharmaceuticals

June 09, 2016

New York/Los Angeles – Paul Hastings LLP, a leading global law firm, represented Merck, known as MSD outside the United States and Canada, in a definitive agreement under which Merck will acquire Afferent Pharmaceuticals, a privately held pharmaceutical company.

Afferent Pharmaceuticals is a leader in the development of therapeutic candidates targeting the P2X3 receptor for the treatment of common, poorly-managed, neurogenic conditions. Afferent’s lead investigational candidate, AF-219, is a selective, non-narcotic, orally-administered P2X3 antagonist currently being evaluated in a Phase 2b clinical trial for the treatment of refractory, chronic cough as well as in a Phase 2 clinical trial in idiopathic pulmonary fibrosis (IPF) with cough.

The Paul Hastings team was led by M&A partners David Shine and Claudia Simon, in addition to Corporate associates Rachel Harrison, Jordan Goldman, Natasha Chua Tan, and Carolyn Nguyen, and assistance from Sam Waxman, Mike Vargas from M&A/IP, Eric Keller and Kate Robinson from Employment, Kristen Winckler and Dan Greenwald from Tax, Scott Hataway from Antitrust.

At Paul Hastings, our purpose is clear — to help our clients and people navigate new paths to growth. With a strong presence throughout Asia, Europe, Latin America, and the U.S., Paul Hastings is recognized as one of the world’s most innovative global law firms.

Practice Areas

Mergers and Acquisitions

Tax

Corporate

Antitrust and Competition

Life Sciences and Healthcare

Employment Law


SIGN UP FOR NEWS INSIGHTS

MEDIA CONTACTS

Corporate, Litigation, Real Estate, Intellectual Property, Life Sciences, and Employment

Becca Hatton

Paris

Katy Foster

Europe

Miranda Ward

Submission Requests

Firmwide Inquiries

Elliott Frieder